TRACES OF EPSTEIN BARR VIRUS (EBV) ARE NOT INVOLVED IN THE PATHOGENESIS OF DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

Introduction: Epstein-Barr virus-positive DLBCL (EBV+ DLBCL) was defined by the WHO, with >80% EBERs+ cells, although 20% used as cut off. The detection of traces EBV reported more sensitive methods than EBERs in situ hybridization (ISH). aim to analyze immune response markers EBV+ DLBCL, and compare them cases or without infection. Methods: Fifty DLCBL were studied ISH. expression genes evaluated Lymph2Cx. LMP1 EBNA2 transcripts detected double ISH ViewRNA Tissue 2-Plex Assay define presence EBV. LMP1+, EBNA2+, LMP1+/EBNA2+ cells counted tumor cells. Viral load measured RT- qPCR. Immunohistochemistry (IHC) for CD68, CD163, LAG3 PDL1 at TME, PDL1/PAX5 performed. Results: 12/50 cases. A cut-off EBV+DLBCL. 19/45 (5 14 EBV-) good quality analysis. 19 5 expressed transcripts, respectively (Figure 1A,Bfig1). Only EBV+DLBCL displayed detectable viral load. When Lymph2Cx compared versus EBV- higher CD274 (PDL1), LAG3, among others, observed 1C). This increased not when its negative counterpart. CD68 TME assessed IHC validate gene results. PDL1+/ PAX5+ CD68+ cell count (p < 0.05), whereas no difference TME. M1 polarization profile prevailed entire cohort. However, them, differences proved PDL1/ PAX5 count. research funded by: grants from National Agency Science Technology Promotion (PICT 2018 0966, PIDC 0052), CONICET (PUE 0048) Keywords: microenvironment, non-Hodgkin (pediatric, adolescent, young adult), biology heterogeneity No conflicts interests pertinent abstract.